Navigation Links
AssureRx Health Launches Personalized Medicine Test for ADHD
Date:5/7/2012

MASON, Ohio, May 7, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

GeneSightRx ADHD analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults.  Understanding a patient's unique genomic profile may help a clinician individualize a patient's medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.

The GeneSightRx ADHD analysis is based on pharmacogenomics, FDA-approved manufacturer's drug labels, published peer reviewed research, and proven pharmacology. The new ADHD test adds to the company's treatment decision support products that include GeneSightRx Psychotropic, a psychiatric pharmacogenomic product that tests important genomic variants affecting metabolism to psychiatric medications for individual patients. 

ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood. Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.

"ADHD is a neurobehavioral disorder affecting millions of children and adults. With the introduction of GeneSightRx ADHD, clinicians now have an objective, evidence-based tool for individualizing ADHD medications," said James S. Burns, president and CEO of AssureRx Health.&
'/>"/>

SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
2. AssureRx Health Raises $11 Million Series B Financing
3. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
4. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
5. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
6. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
7. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
8. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
10. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
11. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... Pinnacle hip replacement lawsuit ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) now ... of Texas has moved into its third week, ... this week’s witnesses included a DePuy Orthopaedics vice ... performed on the metal-on-metal Pinnacle hip. * (Herlihy-Paoli ...
(Date:9/16/2014)... School of Medicine have launched a phase 1 human ... a new monoclonal antibody for patients with chronic lymphocytic ... in adults. , The new antibody targets ... development and exploited by cancer cells to promote tumor ... of all cancer-related deaths. , Because ROR1 ...
(Date:9/16/2014)... 16, 2014 RxAnte, the leading ... and targeted clinical programs, today announced key changes ... the Company’s drive to improve medication effectiveness through ... programs. On September 2, 2014, Brock Hardaway, chief ... announced that RxAnte founder and President Josh Benner ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Former Major ... today after undergoing successful heart transplantation surgery at Allegheny ... Tekulve, who spent most of his 16-year baseball career ... as a commentator for Root Sports Pittsburgh, was discharged ... surgeon, Stephen Bailey, MD, surgical director of AGH’s heart ...
(Date:9/16/2014)... no longer be used to ascertain the eventual scale ... University of Warwick. , Dr Thomas House, of the ... data from past outbreaks that successfully replicated their eventual ... Ebola Outbreaks and published by eLife , shows ... 2014 outbreak to the model that it is, according ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Latest Testimony in Federal Pinnacle Hip Replacement Trial 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Latest Testimony in Federal Pinnacle Hip Replacement Trial 3Health News:Novel drug targeting leukemia cells enters clinical trial 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2
... of the outcomes of medical tests whose results are ... is common and can lead to serious medical errors ... by researchers from the Regenstrief Institute and the Indiana ... summaries are grossly inadequate at documenting both tests with ...
... - Hard to Treat Diseases, Inc. (HTDS:PK), ( http://www.htdsmedical.com ... (Mellow Hope) announced today that the general manager of ... to a significant new business development opportunity related to ... to participate in a formal tender process to supply ...
... , JEDDAH, Saudi Arabia, Aug. 7 ... about themselves, and Saudi women are no exception. But is ... strong guiding force in the kingdom? Read about how plastic ... , http://susiesbigadventure.blogspot.com/2009/08/plastic-surgery-in-saudi-arabia.html , ...
... if fall outbreak proves more severe, government says , ... that swept across the United States last spring during ... repeated this fall, according to new guidelines issued Friday ... noted that everything could change if the outbreak suddenly ...
... Aug. 7 Pharmaceutical Institute, a leading provider of specialized ... that Garry O,Grady has been appointed Senior Vice President and ... Mr. O,Grady will manage the day-to-day operations of the business, ... and sales teams. , , Mr. O,Grady ...
... , , NEW YORK, Aug. 7 ... need additional vaccines beyond those received when they were infants or ... (CDC) estimates, most pre-teens and teens do not have all the ... risks for certain diseases and protection from some childhood vaccines can ...
Cached Medicine News:Health News:Fumbled handoffs can lead to medical errors 2Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 2Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 3Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 4Health News:School Closures May Not Be Necessary When Swine Flu Strikes 2Health News:School Closures May Not Be Necessary When Swine Flu Strikes 3Health News:School Closures May Not Be Necessary When Swine Flu Strikes 4Health News:Garry O'Grady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 2Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 2Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 3
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
... first time in the world, there is a ... to diagnose VVC in female patients. CanDia5® is ... detect the Candida antigens almost instantaneously (within 5 ... blood. There is no similar POC product for ...
... test for Candida albicans in only ... utilizes two enzyme color reactions to ... to read. AlbiQuicktm is performed on ... wells. Incubation time is only five ...
Medicine Products: